109 firms have their name on a GLP-1 listing with FDA

Who supplies each molecule

Firms with at least one listing of each kind. Read across: a firm counts once per column.

Retatrutide has no approved listing: every retatrutide entry in the directory is a bulk ingredient listing.

What a listing means, and what it does not

“Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“Assignment of an NDC number does not in any way denote FDA approval of the product.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

“A labeler may be a manufacturer, including a repackager or relabeler, or the entity named on the product label.”FDA, National Drug Code Directory page, confirmed on the page Oct 4, 2026. fda.gov ↗

• Approved product. A finished product sold under an approved application (NDA, BLA or ANDA). The approval belongs to the application, which Drugs@FDA lists with its holder; the NDC is only the product's identifier.
• 503B compounded. A drug a 503B outsourcing facility compounded and reported to FDA. FDA's own category name for these is "exempt from approval requirements": nobody has approved the product.
• Unfinished, for further processing. Drug made to be processed further by another firm (filled, packed or finished elsewhere), not sold to patients in this form.
• Bulk ingredient. The active ingredient itself, as powder or solution, sold to manufacturers or, where the listing says so, to compounders. A listing tells FDA the firm makes or sells it; it is not an approval of the ingredient or of anything made from it.

Every firm on a GLP-1 listing

“Federal record” counts matches we can confirm: recalls and shortages by an NDC FDA printed, warning letters and the 503B register by exact firm name. Similar names are shown on the firm’s page and never counted here.

Firms with more on file than a listing

Sources and limits

• Listings: FDA’s NDC directory through openFDA ↗, every listing whose active ingredient is semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, orforglipron, retatrutide; updated by FDA Oct 2, 2026.
• 503B products: FDA’s compounded drugs file ↗, last replaced by FDA Sep 18, 2026. FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.”
• Application holders and first approval dates: Drugs@FDA through openFDA, updated by FDA Oct 2, 2026.
• Joined to the GLP-1 records we already publish: warning letters, recalls and the 503B register.
• Firms are grouped when FDA lists the same name with different punctuation, or two names under one labeler code. The directory leaves out drugs made under contract, and a listing’s content is the labeler’s responsibility, not FDA’s. Read by us Oct 4, 2026.